I. Mehmi

发表

Abstract CT144: Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma

J. Kirkwood, A. Ribas, M. Milhem, 2018, Clinical Trials.

Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo.

R. Lupu, Careen K. Tang, E. Atlas, 2003, Molecular cancer research : MCR.

Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.

J. Menéndez, R. Lupu, E. Atlas, 2004, International journal of oncology.

Expression and regulation of Cyr61 in human breast cancer cell lines

R. Lupu, M. Tsai, Miaw-Sheue Tsai, 2002, Oncogene.

Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.

A. Hauschild, K. Kähler, P. Ascierto, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Delaying Chemotherapy in the Treatment of Stage IV Non-Small Cell Lung Cancer Does Not Adversely Affect Survival Outcome

I. Mehmi, T. Gress, M. Tirona, 2016 .

SARS-CoV-2 vaccine uptake, perspectives, and adverse reactions following vaccination in patients with cancer undergoing treatment

A. Mita, O. Hamid, J. Gong, 2021, Annals of Oncology.

New Checkpoint Inhibitors and Immunotherapies for Solid Tumours

I. Mehmi, O. Hamid, K. Wentzel, 2021, Oncology & Haematology.

A unique case of chronic myeloid leukemia presenting as monocular vision loss with unilateral retinopathy

M. Seraly, I. Mehmi, L. Veltri, 2019, American journal of ophthalmology case reports.

Adhering to the guidelines: rates of BRCA mutation using NCCN genetic testing criteria

Jaime, Shaheen, J. Kirkwood, 2017 .

Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer

S. Verdura, E. Cuyás, J. Menéndez, 2021, Cancers.

Eflapegrastim, a Long‐Acting Granulocyte‐Colony Stimulating Factor for the Management of Chemotherapy‐Induced Neutropenia: Results of a Phase III Trial

L. Schwartzberg, I. Mehmi, S. Chawla, 2020, The oncologist.

A deletion mutant of heregulin increases the sensitivity of breast cancer cells to chemotherapy without promoting tumorigenicity

R. Lupu, E. Atlas, I. Mehmi, 2003, Oncogene.

Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel me

S. Ropero, J. Menéndez, R. Lupu, 2004, International journal of oncology.

Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer

D. McGovern, R. Paquette, J. V. Van Eyk, 2021, Cancer Research.

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma

M. Weichenthal, K. Kähler, P. Ascierto, 2022, Journal for ImmunoTherapy of Cancer.

Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells

J. Menéndez, R. Lupu, E. Atlas, 2004, Oncogene.

304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma

Katie M. Campbell, D. Davar, J. Kirkwood, 2020 .

Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer

R. Lupu, Careen K. Tang, M. Tsai, 2003, Oncogene.

Endogenous aryl hydrocarbon receptor promotes basal and inducible expression of tumor necrosis factor target genes in MCF-7 cancer cells.

Jun Fan, N. Santanam, I. Mehmi, 2014, Biochemical pharmacology.

A novel CYR61-triggered ‘CYR61-αvβ3 integrin loop’ regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway

D. Griggs, J. Menéndez, R. Lupu, 2005, Oncogene.

Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells.

S. Ropero, J. Menéndez, R. Lupu, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Pharmacological inhibition of fatty acid synthase (FAS): A novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her‐2/neu (erbB‐2) oncogene‐induced malignant transformation

J. Menéndez, R. Lupu, Vishal A. Verma, 2004, Molecular carcinogenesis.

Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression.

J. Menéndez, R. Lupu, I. Mehmi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ipilimumab, nivolumab and tocilizumab as first-line therapy for advanced melanoma.

F. Hodi, O. Hamid, J. Weber, 2021 .

The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives.

D. Griggs, J. Menéndez, R. Lupu, 2003, Endocrine-related cancer.

International Congress on Hormonal Steroids and Hormones and Cancer The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives

D. Griggs, R. Lupu, I. Mehmi, 2003 .

Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage.

J. Menéndez, R. Lupu, I. Mehmi, 2005, International journal of oncology.

Black cohosh, a menopausal remedy, does not have estrogenic activity and does not promote breast cancer cell growth.

R. Lupu, E. Kennelly, E. Atlas, 2003, International journal of oncology.

1040O Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma

R. Sullivan, F. Hodi, O. Hamid, 2021, Annals of Oncology.

Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer

S. Verdura, E. Cuyás, J. Menéndez, 2020, International journal of molecular sciences.

Immunotherapy of cancer in the era of checkpoint inhibitor

I. Mehmi, O. Hamid, 2021, Clinical and Experimental Metastasis.

950 Final analysis: phase 1b study investigating intratumoral injection of toll-like receptor 9 agonist vidutolimod ± pembrolizumab in patients with PD-1 blockade–refractory melanoma

D. Davar, J. Kirkwood, A. Ribas, 2021, Journal for ImmunoTherapy of Cancer.

Bilateral uveitis associated with nivolumab therapy for metastatic melanoma: a case report.

Daniel R. Richardson, I. Mehmi, M. Leys, 2017, International journal of ophthalmology.

Metastatic Sarcomatoid Carcinoma of the Small Intestine: a Case Report of Rare Tumor with Literature Review

A. Arrington, I. Mehmi, A. Raufi, 2016, Journal of Gastrointestinal Cancer.

135P First-in-human phase I trial of SRF617, a potent inhibitor of CD39 activity, as monotherapy or in combination, in patients (pts) with advanced solid tumors

D. Rasco, A. Patnaik, Yangang Xing, 2021, Annals of Oncology.

Abstract CT002: KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma

J. Taube, R. Dummer, R. Scolyer, 2023, Cancer Research.

19O Preliminary safety, antitumor activity and pharmacodynamics results of HIT-IT MEDI1191 (mRNA IL-12) in patients with advanced solid tumours and superficial lesions

T. Marron, B. Carneiro, J. Eyles, 2021 .

Abstract CT183: First-in-human study of MEDI1191 (mRNA encoding IL-12) plus durvalumab in patients (pts) with advanced solid tumors

A. El-Khoueiry, T. Marron, B. Carneiro, 2022, Cancer Research.